These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20540014)

  • 1. [Treatment of atrial fibrillation in dialyzed patients: the role of oral anticoagulants. The cardiologist's point of view].
    Lucreziotti S; Lombardi F
    G Ital Nefrol; 2010; 27(3):222-9. PubMed ID: 20540014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of atrial fibrillation in dialyzed patients: the role of oral anticoagulants. The nephrologist's point of view].
    Scanziani R; Galassi A
    G Ital Nefrol; 2010; 27(3):230-6. PubMed ID: 20540015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in oral anticoagulation for atrial fibrillation.
    Singh M; Adigopula S; Patel P; Kiran K; Khosla S
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):395-407. PubMed ID: 20965952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update].
    Pengo V; De Caterina R
    Ital Heart J Suppl; 2001 Sep; 2(9):972-9. PubMed ID: 11675834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New oral anticoagulants for the prevention of thromboembolism in atrial fibrillation: from clinical evidence to appropriate use].
    Colonna P
    G Ital Cardiol (Rome); 2012 Nov; 13(11 Suppl 1):3S-10S. PubMed ID: 23160014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ANMCO statement on prevention of thromboembolism in atrial fibrillation and role of the new oral anticoagulants].
    Colonna P; Abrignani MG; Colivicchi F; Verdecchia P; Alunni G; Bongo AS; Ceravolo R; Oliva F; Rakar S; Riccio C; Scherillo M; Valle R; Bovenzi F;
    G Ital Cardiol (Rome); 2013 Apr; 14(4):295-322. PubMed ID: 23567775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nonvalvular atrial fibrillation: thromboembolic risk assessment and therapy in a general practice population].
    Del Zotti F; Gottardi G; Frapporti G; Micchi A; Zanolla L
    G Ital Cardiol (Rome); 2010 Apr; 11(4):313-7. PubMed ID: 20677578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticoagulant therapy in patients with atrial fibrillation on dialysis: between the risk of hemorrhage and vascular calcification].
    Cozzolino M; Ronga C; Cusi D
    G Ital Nefrol; 2010; 27(3):237-9. PubMed ID: 20540016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thromboembolic risk in atrial fibrillation: new clinical perspectives].
    Villani GQ; Andreoli AM; Villani M; Capucci A
    G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):22S-26S. PubMed ID: 19195302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
    Durin O; Donato G; Nanetti M; Foffa A; Inama G
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):16S-20S. PubMed ID: 23096369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.
    Anderson DR; Gardner MJ; Putnam W; Jassal D; Brownell B; Flowerdew G; Nagpal S; Thompson K; Cox JL
    Can J Cardiol; 2005 Mar; 21(3):257-66. PubMed ID: 15776115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
    Garton AB; Dudzinski J; Kowey PR
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1411-8. PubMed ID: 25216104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
    Ruiz-Nodar JM; Marín F; Hurtado JA; Valencia J; Pinar E; Pineda J; Gimeno JR; Sogorb F; Valdés M; Lip GY
    J Am Coll Cardiol; 2008 Feb; 51(8):818-25. PubMed ID: 18294566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation.
    Nieuwlaat R; Olsson SB; Lip GY; Camm AJ; Breithardt G; Capucci A; Meeder JG; Prins MH; Lévy S; Crijns HJ;
    Am Heart J; 2007 Jun; 153(6):1006-12. PubMed ID: 17540203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk stratification for thromboembolism and antithrombotic prophylaxis in atrial fibrillation].
    Di Pasquale G; Riva L
    G Ital Cardiol (Rome); 2012 Nov; 13(11 Suppl 1):11S-18S. PubMed ID: 23160015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stroke risk stratification in atrial fibrillation: oral anticoagulant therapy and bleeding risk in the elderly].
    Poli D; Grifoni E
    Recenti Prog Med; 2011 Jan; 102(1):23-7. PubMed ID: 21516668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism.
    Torn M; van der Meer FJ; Rosendaal FR
    Arch Intern Med; 2004 Mar; 164(6):668-73. PubMed ID: 15037497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.